BTCC / BTCC Square / Global Cryptocurrency /

Johnson & Johnson Shares Surge on Oncology and Immunology Pipeline Breakthroughs

Johnson & Johnson Shares Surge on Oncology and Immunology Pipeline Breakthroughs

Author:

Global Cryptocurrency

Published:

2025-12-11 07:33:02

7

3

BTCCSquare news:

Johnson & Johnson (NYSE: JNJ) rallied 3.29% to $206.54, nearing its 52-week high, as investors cheered robust clinical updates across its oncology and immunology divisions. The pharmaceutical giant's year-to-date gain now stands at nearly 40%, outpacing both healthcare indices and biotech peers.

Key catalysts include groundbreaking multiple myeloma data for Tecvayli combinations and Carvykti updates, solidifying JNJ's dominance in hematologic cancers. Immunology prospects brightened with icotrokinra's progress, offsetting patent cliff concerns. However, persistent talc litigation remains an overhang on an otherwise strengthening investment thesis.

By:

Salesforce Stock Rises on AI Expansion and DeVry University Deployment

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2025 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.